Axol Bioscience Appoints Liam Taylor as CEO

August 28, 2020
BioPharm International Editors

The company has appointed Liam Tayler as CEO to guide the growth of the company’s iPSC technologies, products, and services.

Cambridge, UK-based Axol Bioscience, a biotechnology company specializing in cell-based assay systems derived from stem cell technology for drug discovery, has appointed Liam Taylor as CEO to guide the growth of the company by focusing on its induced pluripotent stem cell (iPSC) technologies, products and services and by maximizing team potential, Axol announced in an Aug. 26, 2020 press release.

Liam is highly experienced with extensive knowledge of running commercial, operations, finance, and innovation teams in the diagnostic, pharma, and life science sector, both in the United Kingdom and the United States. He was previously chief financial officer, then managing director, of BBI Solutions. During Liam’s tenure at BBI solutions, the company’s annual revenues grew from £23 million (US$31 million) to over £52 million (US$69 million), driven by organic growth and strategic acquisitions.

“The Board is delighted to appoint Liam as Axol’s new CEO. His wealth of experience and comprehensive knowledge of the pharma and life science sector will be invaluable in unlocking the full potential of the [c]ompany,” said Jonathan Milner, chairman, Axol Bioscience, in the company press release.

“The progress achieved at Axol Bioscience in developing high quality and consistent iPSCs has been impressive, and I am excited to be joining at an exciting point in the [c]ompany’s development, where we will be working to scale up operations to support the rapidly growing biotech and pharmaceutical markets, to support increases in efficiency within drug screening and discovery,” Taylor added in the press release.

Source: Axol Bioscience